Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti–Programmed Cell Death (Ligand)1 and Sotorasib Therapy in KRASG12C-Mutant Lung Cancer-Reference-Cited by-同舟云学术

Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti–Programmed Cell Death (Ligand)1 and Sotorasib Therapy in KRASG12C-Mutant Lung Cancer

Published:2023-10 Issue:10 Volume:18 Page:1408-1415
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Chour Ali,Denis Julie,Mascaux Céline,Zysman Maeva,Bigay-Game Laurence,Swalduz Aurélie,Gounant Valérie,Cortot Alexis,Darrason Marie,Fallet Vincent,Auclin Edouard,Basse Clémence,Tissot Claire,Decroisette Chantal,Bombaron Pierre,Giroux-Leprieur Etienne,Odier Luc,Brosseau Solenn,Creusot Quentin,Gueçamburu Marina,Meersseman Corentin,Rochand Adrien,Costantini Adrien,Gaillard Claire Marine,Wasielewski Eric,Girard Nicolas,Cadranel Jacques,Lafitte Claire,Lebossé Fanny,Duruisseaux Michaël^ORCID

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference16 articles.

1. RAS proteins and their regulators in human disease;Simanshu;Cell,2017

2. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial;de Langen;Lancet,2023

3. Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib;Schoenfeld;Ann Oncol,2019

4. EGFR-TKI-associated interstitial pneumonitis in nivolumab-treated patients with non-small cell lung cancer;Oshima;JAMA Oncol,2018

5. Hypersensitivity reactions to selpercatinib treatment with or without prior immune checkpoint inhibitor therapy in patients with NSCLC in LIBRETTO-001;McCoach;J Thorac Oncol,2022

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanisms of resistance to KRASG12C inhibitors in KRASG12C-mutated non-small cell lung cancer;Frontiers in Oncology;2024-09-05

2. Toxicities associated with sequential or combined use of immune checkpoint inhibitors and small targeted therapies in non-small cell lung cancer: A critical review of the literature;Cancer Treatment Reviews;2024-09

3. A real-world pharmacovigilance study of KRAS G12C mutation inhibitors based on the food and drug administration adverse event reporting system;Frontiers in Pharmacology;2024-08-28

4. Zielgerichtete Therapie des nichtkleinzelligen Lungenkarzinoms;Die Onkologie;2024-08-15

5. PDP1 promotes KRAS mutant colorectal cancer progression by serving as a scaffold for BRAF and MEK1;Cancer Letters;2024-08